Response to anti-PD-1 in microsatellite stable colorectal cancer: a STAT need.

Most colorectal cancers are microsatellite stable with no response to anti-PD-1 therapy, necessitating the development of new immunomodulatory treatment strategies. Co-inhibition of anti-PD-1 and STAT3 can elicit an effective anti-tumor response in a small subset of microsatellite stable colorectal cancer patients, and biomarkers predictive of response are under investigation.